A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

被引：168

作者：

Goff, DC

Leahy, L

Berman, I

Posever, T

Herz, L

Leon, AC

Johnson, SA

Lynch, G

机构：

[1] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA

[2] Cortex Pharmaceut, Irvine, CA USA

[3] Cornell Univ, Weill Med Coll, Dept Psychiat, New York, NY USA

[4] Vet Affairs Med Ctr, Bedford, MA USA

[5] Tufts Univ, Sch Med, Boston, MA 02111 USA

[6] Lemmuel Shattuck Hosp, Boston, MA USA

[7] Taunton State Hosp, Taunton, MA USA

[8] Harvard Univ, Sch Med, Boston, MA USA

[9] Massachusetts Gen Hosp, Psychiat Serv, Boston, MA 02114 USA

来源：

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | 2001年 / 21卷 / 05期

关键词：

D O I：

10.1097/00004714-200110000-00005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

CX516, a positive modulator of the glutamatergic alpha -amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor, improves performance in tasks requiring learning and memory in animals. CX516 was added to clozapine in 4-week, placebo-controlled, dose-finding (N = 6) and fixed-dose (N = 13) trials. CX516 was tolerated well and was associated with moderate to large, between-group effect sizes compared with placebo, representing improvement in measures of attention and memory. These preliminary results suggest that CX516 and other "ampakines" hold promise for the treatment of schizophrenia.

引用

页码：484 / 487

页数：4

共 17 条

[1] Arai A, 1996, J PHARMACOL EXP THER, V278, P627
[2] Cohen J., 1998, Statistical Power Analysis for the Behavioral Sciences, V2nd
[3] FRONTAL CORTICAL AND LEFT TEMPORAL GLUTAMATERGIC DYSFUNCTION IN SCHIZOPHRENIA
DEAKIN, JFW
SLATER, P
SIMPSON, MDC
GILCHRIST, AC
SKAN, WJ
ROYSTON, MC
REYNOLDS, GP
CROSS, AJ
[J]. JOURNAL OF NEUROCHEMISTRY, 1989, 52 (06) : 1781 - 1786
[4] DECREASED EXPRESSION OF MESSENGER-RNAS ENCODING NON-NMDA GLUTAMATE RECEPTORS GLUR1 AND GLUR2 IN MEDIAL TEMPORAL-LOBE NEURONS IN SCHIZOPHRENIA
EASTWOOD, SL
MCDONALD, B
BURNET, PWJ
BECKWITH, JP
KERWIN, RW
HARRISON, PJ
[J]. MOLECULAR BRAIN RESEARCH, 1995, 29 (02): : 211 - 223
[5] Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus:: Effects of schizophrenia
Gao, XM
Sakai, K
Roberts, RC
Conley, RR
Dean, B
Tamminga, CA
[J]. AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (07) : 1141 - 1149
[6] A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
Goff, DC
Tsai, G
Levitt, J
Amico, E
Manoach, D
Schoenfeld, DA
Hayden, DL
McCarley, R
Coyle, JT
[J]. ARCHIVES OF GENERAL PSYCHIATRY, 1999, 56 (01) : 21 - 27
[7] Hampson RE, 1998, J NEUROSCI, V18, P2748
[8] DECREASED HIPPOCAMPAL EXPRESSION OF A GLUTAMATE RECEPTOR GENE IN SCHIZOPHRENIA
HARRISON, PJ
MCLAUGHLIN, D
KERWIN, RW
[J]. LANCET, 1991, 337 (8739) : 450 - 452
[9] Johnson SA, 1999, J PHARMACOL EXP THER, V289, P392
[10] QUANTITATIVE AUTORADIOGRAPHIC ANALYSIS OF GLUTAMATE BINDING-SITES IN THE HIPPOCAMPAL-FORMATION IN NORMAL AND SCHIZOPHRENIC BRAIN POSTMORTEM
KERWIN, R
PATEL, S
MELDRUM, B
[J]. NEUROSCIENCE, 1990, 39 (01) : 25 - 32

← 1 2 →